ANRO
Price:
$13.38
Market Cap:
$415.67M
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO...[Read more]
Industry
Biotechnology
IPO Date
2024-02-02
Stock Exchange
NYSE
Ticker
ANRO
According to Alto Neuroscience, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.82. This represents a change of 181.32% compared to the average of -2.07 of the last 4 quarters.
The mean historical PE Ratio of Alto Neuroscience, Inc. over the last ten years is -23.44. The current -5.82 PE Ratio has changed 2.38% with respect to the historical average. Over the past ten years (40 quarters), ANRO's PE Ratio was at its highest in in the June 2025 quarter at -0.84. The PE Ratio was at its lowest in in the March 2023 quarter at -19.10.
Average
-23.44
Median
-17.22
Minimum
-57.62
Maximum
-1.69
Discovering the peaks and valleys of Alto Neuroscience, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = -1.69
Minimum Annual Increase = -88.95%
Minimum Annual PE Ratio = -57.62
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -1.69 | -88.95% |
| 2023 | -15.33 | -19.77% |
| 2022 | -19.10 | -66.85% |
The current PE Ratio of Alto Neuroscience, Inc. (ANRO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-12.04
5-year avg
-23.44
10-year avg
-23.44
Alto Neuroscience, Inc.’s PE Ratio is greater than Cellectis S.A. (-8.40), less than AC Immune S.A. (-4.60), greater than Amarin Corporation plc (-79.20), less than Larimar Therapeutics, Inc. (-2.36), less than Contineum Therapeutics, Inc. Class A Common Stock (-5.20), less than Aldeyra Therapeutics, Inc. (-5.79), greater than Alpha Tau Medical Ltd. (-8.51), less than Silence Therapeutics plc (-1.93), less than Korro Bio, Inc. (-0.70), less than DBV Technologies S.A. (-2.92),
| Company | PE Ratio | Market cap |
|---|---|---|
| -8.40 | $484.47M | |
| -4.60 | $289.73M | |
| -79.20 | $340.44M | |
| -2.36 | $314.97M | |
| -5.20 | $320.40M | |
| -5.79 | $293.49M | |
| -8.51 | $346.14M | |
| -1.93 | $336.78M | |
| -0.70 | $63.86M | |
| -2.92 | $312.18M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alto Neuroscience, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Alto Neuroscience, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Alto Neuroscience, Inc.'s PE Ratio?
How is the PE Ratio calculated for Alto Neuroscience, Inc. (ANRO)?
What is the highest PE Ratio for Alto Neuroscience, Inc. (ANRO)?
What is the 3-year average PE Ratio for Alto Neuroscience, Inc. (ANRO)?
What is the 5-year average PE Ratio for Alto Neuroscience, Inc. (ANRO)?
How does the current PE Ratio for Alto Neuroscience, Inc. (ANRO) compare to its historical average?